Developer docs
API playgroundTry for free, no card

Search company profiles

Solve Therapeutics

Full company profile

uuid0000m2u

Namestring
Solve Therapeutics
Legal namestring
Solve Therapeutics, Inc.
Websiteurl
solvetx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Solve Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2021 and headquartered in Belmont, California, with research and development operations in San Diego, California and Durham, North Carolina. The company develops next-generation antibody-drug conjugates (ADCs) for solid tumor malignancies, with two lead programs — SLV-154 and SLV-324 — currently in Phase 1 clinical trials and a third undisclosed ADC candidate (ADC 3) advancing through earlier development. Its core platform is CloakLink™, a proprietary hydrophilic cleavable linker system engineered to mask the hydrophobic properties of cytotoxic payloads, enabling enhanced plasma stability, improved pharmacokinetics, reduced off-target toxicity, and bystander killing of neighboring cancer cells; CloakLink is designed to be compatible with a wide range of payloads, drug-antibody ratios, and targeting antibodies. In June 2023 the company acquired Cereius, Inc., a Duke University spin-out developing targeted radiodiagnostics and radiotherapeutics, adding a radiolabeling platform and North Carolina laboratory capacity, and the company pairs its ADCs with a novel companion diagnostic approach intended to enable precision patient selection.

Solve Therapeutics does not yet have commercialized products and is pre-revenue; its go-to-market model is the standard pharmaceutical development pathway — clinical trials at oncology research sites, regulatory approval, and eventual distribution through hospitals, oncology clinics, and specialty pharmacies, with potential companion diagnostic revenue and licensing/royalty streams. Target end users are patients with solid tumor cancers who have high unmet medical need for targeted therapies with improved safety and efficacy profiles, reached indirectly via treating oncologists and healthcare institutions. The customer-facing channel today is therefore enterprise-style engagement with clinical trial sites and institutional investigators rather than direct sales.

The company is led by a reconstituted VelosBio (acquired by Merck for $2.75 billion) and Acerta Pharma (acquired by AstraZeneca for $7 billion) leadership team, including CEO Dave Johnson, President Clayton Knox, MD, and EVP Research Brian Lannutti, with additional senior leadership spanning translational sciences, manufacturing/CMC, theragnostics, protein technology, finance, and operations. Through November 2025 Solve has raised approximately $321 million in cumulative funding from a syndicate including Yosemite, Merck & Co., Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, SymBiosis, General Atlantic, Alexandria Venture Investments, Surveyor Capital, and others.

Short descriptiontext

Solve Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for solid tumors using its proprietary CloakLink hydrophilic linker platform, with two lead programs in Phase 1 trials and a radiopharmaceutical subsidiary acquired from Cereius.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics, biopharmaceutical development, targeted cancer therapy, clinical stage research
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1ADC Therapeutic Pipeline
TypeOne Time License
Description

Solve Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for solid tumor malignancies. The company has two lead programs (SLV-154 and SLV-324) in Phase 1 clinical trials. Revenue will be generated through commercialization of therapeutic products following regulatory approval.

solvetx.com
2Diagnostic Platform
TypeLicensing Royalties
Description

Novel diagnostic approach integrated with ADC therapeutics for precision patient selection. Revenue may be generated through companion diagnostic products or licensing of diagnostic technology.

solvetx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Solve Therapeutics is a clinical-stage biopharmaceutical company developing Antibody Drug Conjugates (ADCs) and Bispecific Therapeutics for solid tumor malignancies. Its lead ADC programs, SLV-154 and SLV-324, are in Phase 1 clinical trials, with a third preclinical ADC (ADC 3) and a Bispecific Therapeutic Platform in earlier-stage development. The company leverages its proprietary CloakLink™ hydrophilic linker technology to design ADCs with enhanced plasma stability, improved pharmacokinetics, and reduced off-target toxicity, and complements this with a companion Diagnostic Platform for precision patient identification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Two lead programs (SLV-154 and SLV-324) in Phase 1 clinical trials as of November 2025
+1 more record
Product and service4 records
1SLV-154
CategoryOncology Biopharmaceuticals / ADC Therapeutics
Description

SLV-154 is a Phase 1 antibody drug conjugate (ADC) being developed by Solve Therapeutics for the treatment of solid tumor malignancies. It is one of the company's two lead ADC programs.

2SLV-324
CategoryOncology Biopharmaceuticals / ADC Therapeutics
Description

SLV-324 is a Phase 1 antibody drug conjugate (ADC) being developed by Solve Therapeutics for the treatment of solid tumor malignancies. It is one of the company's two lead ADC programs, alongside SLV-154.

3ADC 3
CategoryOncology Biopharmaceuticals / ADC Therapeutics
Description

ADC 3 is an earlier-stage, preclinical antibody drug conjugate in Solve Therapeutics' pipeline, intended for the treatment of solid tumor malignancies.

4Companion Diagnostic Platform
CategoryCompanion Diagnostics / Precision Medicine
Description

The Companion Diagnostic Platform is a precision-medicine diagnostic offering intended to identify patients most likely to benefit from Solve Therapeutics' ADC therapies. It is being developed to be paired with the company's ADC pipeline, and the company has indicated potential revenue from licensing the diagnostic technology.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-22
Description

Solve Therapeutics acquired Cereius, Inc., a Duke University oncology spin-out focused on radiodiagnostics and radiotherapeutics for cancer. The acquisition incorporated Cereius's radiolabeling technology platform and facilities in North Carolina, enhancing SolveTx's oncology therapeutic arsenal. Deal included upfront payments, milestone payments, and royalties based on sales of products developed from Cereius's technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ADC leader (Adcetris, Padcev, Tukysa, Tivdak) acquired by Pfizer for $43B. Directly comparable as a clinical-to-commercial ADC developer with proprietary linker technology and a focus on oncology.

TypeBroad incumbent
Description

Acquired Acerta Pharma (Solve CEO Dave Johnson's prior company) for $7B and now markets Calquence. Comparable both as a large oncology player and as the acquirer of Solve leadership's prior ADC/small-molecule platform.

TypeEmerging player
Description

Clinical-stage ADC developer focused on solid tumors with proprietary linker technology. Comparable as an early-stage ADC platform peer that was acquired by Genmab in 2024.

TypeBroad incumbent
Description

Co-developer of Enhertu and Datroway with AstraZeneca, operating a broad oncology portfolio with deep ADC capabilities. Directly comparable as a major-pharma ADC competitor and potential strategic acquirer of Solve.

TypeDirect peer
Description

Pioneer in ADC technology with approved products (Elahere) and a deep linker/payload IP estate acquired by AbbVie. Highly comparable as an ADC platform company developing solid-tumor ADCs.

TypeEmerging player
Description

Emerging ADC platform company developing proprietary linkers (P5 Conjugate, Tub-tag) for solid tumors. Comparable as an early-stage ADC platform competitor with linker-focused differentiation.

TypeEmerging player
Description

Clinical-stage ADC developer (microtubule-inhibitor and topoisomerase-based payloads) with a focus on solid tumors. Comparable as a similarly staged, similarly capitalized ADC competitor.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary linker and payload platforms (Dolasynthen, Immunosynthen) targeting solid tumors. Closely comparable ADC platform company at similar stage of development.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical/theranostics company. Comparable via the Cereius-acquired radiopharmaceutical platform at Solve, especially in targeted radiodiagnostics and radiotherapeutics for solid tumors.

TypeDirect peer
Description

Founded by Solve CEO Dave Johnson, VelosBio developed ROR1-directed ADCs (including VLS-101/zilovertamab vedotin) and was acquired by Merck for $2.75B. It is the most directly comparable antecedent to Solve in terms of team, modality, and exit pathway.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solve Therapeutics

Oncology Biopharmaceuticalssolvetx.com

Solve Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for solid tumors using its proprietary CloakLink hydrophilic linker platform, with two lead programs in Phase 1 trials and a radiopharmaceutical subsidiary acquired from Cereius.

What Solve Therapeutics does

Solve Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2021 and headquartered in Belmont, California, with research and development operations in San Diego, California and Durham, North Carolina. The company develops next-generation antibody-drug conjugates (ADCs) for solid tumor malignancies, with two lead programs — SLV-154 and SLV-324 — currently in Phase 1 clinical trials and a third undisclosed ADC candidate (ADC 3) advancing through earlier development. Its core platform is CloakLink™, a proprietary hydrophilic cleavable linker system engineered to mask the hydrophobic properties of cytotoxic payloads, enabling enhanced plasma stability, improved pharmacokinetics, reduced off-target toxicity, and bystander killing of neighboring cancer cells; CloakLink is designed to be compatible with a wide range of payloads, drug-antibody ratios, and targeting antibodies. In June 2023 the company acquired Cereius, Inc., a Duke University spin-out developing targeted radiodiagnostics and radiotherapeutics, adding a radiolabeling platform and North Carolina laboratory capacity, and the company pairs its ADCs with a novel companion diagnostic approach intended to enable precision patient selection.

Solve Therapeutics does not yet have commercialized products and is pre-revenue; its go-to-market model is the standard pharmaceutical development pathway — clinical trials at oncology research sites, regulatory approval, and eventual distribution through hospitals, oncology clinics, and specialty pharmacies, with potential companion diagnostic revenue and licensing/royalty streams. Target end users are patients with solid tumor cancers who have high unmet medical need for targeted therapies with improved safety and efficacy profiles, reached indirectly via treating oncologists and healthcare institutions. The customer-facing channel today is therefore enterprise-style engagement with clinical trial sites and institutional investigators rather than direct sales.

The company is led by a reconstituted VelosBio (acquired by Merck for $2.75 billion) and Acerta Pharma (acquired by AstraZeneca for $7 billion) leadership team, including CEO Dave Johnson, President Clayton Knox, MD, and EVP Research Brian Lannutti, with additional senior leadership spanning translational sciences, manufacturing/CMC, theragnostics, protein technology, finance, and operations. Through November 2025 Solve has raised approximately $321 million in cumulative funding from a syndicate including Yosemite, Merck & Co., Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, SymBiosis, General Atlantic, Alexandria Venture Investments, Surveyor Capital, and others.

Solve Therapeutics firmographics

Firmographics
Name
Solve Therapeutics
Legal name
Solve Therapeutics, Inc.
Website
https://solvetx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Solve Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for solid tumors using its proprietary CloakLink hydrophilic linker platform, with two lead programs in Phase 1 trials and a radiopharmaceutical subsidiary acquired from Cereius.
Ownership category
akta.pro rank

Solve Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics
  • Biopharmaceutical development
  • Targeted cancer therapy
  • Clinical stage research

Where Solve Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Solve Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. ADC Therapeutic Pipeline: Solve Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for solid tumor malignancies. The company has two lead programs (SLV-154 and SLV-324) in Phase 1 clinical trials. Revenue will be generated through commercialization of therapeutic products following regulatory approval.
  2. Diagnostic Platform: Novel diagnostic approach integrated with ADC therapeutics for precision patient selection. Revenue may be generated through companion diagnostic products or licensing of diagnostic technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Solve Therapeutics product offering

Product offering

Core offering

Solve Therapeutics is a clinical-stage biopharmaceutical company developing Antibody Drug Conjugates (ADCs) and Bispecific Therapeutics for solid tumor malignancies. Its lead ADC programs, SLV-154 and SLV-324, are in Phase 1 clinical trials, with a third preclinical ADC (ADC 3) and a Bispecific Therapeutic Platform in earlier-stage development. The company leverages its proprietary CloakLink™ hydrophilic linker technology to design ADCs with enhanced plasma stability, improved pharmacokinetics, and reduced off-target toxicity, and complements this with a companion Diagnostic Platform for precision patient identification.

Differentiator

Problem solved

Functional benefit

Products and services

  • SLV-154 SLV-154 is a Phase 1 antibody drug conjugate (ADC) being developed by Solve Therapeutics for the treatment of solid tumor malignancies. It is one of the company's two lead ADC programs.
  • SLV-324 SLV-324 is a Phase 1 antibody drug conjugate (ADC) being developed by Solve Therapeutics for the treatment of solid tumor malignancies. It is one of the company's two lead ADC programs, alongside SLV-154.
  • ADC 3 ADC 3 is an earlier-stage, preclinical antibody drug conjugate in Solve Therapeutics' pipeline, intended for the treatment of solid tumor malignancies.
  • Companion Diagnostic Platform The Companion Diagnostic Platform is a precision-medicine diagnostic offering intended to identify patients most likely to benefit from Solve Therapeutics' ADC therapies. It is being developed to be paired with the company's ADC pipeline, and the company has indicated potential revenue from licensing the diagnostic technology.

Quantifiable outcome

  • Two lead programs (SLV-154 and SLV-324) in Phase 1 clinical trials as of November 2025
  • +1 more outcomes

Companies that use Solve Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Solve Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Solve Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cereius, Inc.coreStrategic or Co-development Partner · 22 June 2023Solve Therapeutics acquired Cereius, Inc., a Duke University oncology spin-out focused on radiodiagnostics and radiotherapeutics for cancer. The acquisition incorporated Cereius's radiolabeling technology platform and facilities in North Carolina, enhancing SolveTx's oncology therapeutic arsenal. Deal included upfront payments, milestone payments, and royalties based on sales of products developed from Cereius's technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Solve Therapeutics competitors and assessment

Company assessment

Direct peers

  • Seagen: ADC leader (Adcetris, Padcev, Tukysa, Tivdak) acquired by Pfizer for $43B. Directly comparable as a clinical-to-commercial ADC developer with proprietary linker technology and a focus on oncology.
  • ImmunoGen: Pioneer in ADC technology with approved products (Elahere) and a deep linker/payload IP estate acquired by AbbVie. Highly comparable as an ADC platform company developing solid-tumor ADCs.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary linker and payload platforms (Dolasynthen, Immunosynthen) targeting solid tumors. Closely comparable ADC platform company at similar stage of development.
  • VelosBio: Founded by Solve CEO Dave Johnson, VelosBio developed ROR1-directed ADCs (including VLS-101/zilovertamab vedotin) and was acquired by Merck for $2.75B. It is the most directly comparable antecedent to Solve in terms of team, modality, and exit pathway.

Broad incumbents

  • AstraZeneca: Acquired Acerta Pharma (Solve CEO Dave Johnson's prior company) for $7B and now markets Calquence. Comparable both as a large oncology player and as the acquirer of Solve leadership's prior ADC/small-molecule platform.
  • Daiichi Sankyo: Co-developer of Enhertu and Datroway with AstraZeneca, operating a broad oncology portfolio with deep ADC capabilities. Directly comparable as a major-pharma ADC competitor and potential strategic acquirer of Solve.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical/theranostics company. Comparable via the Cereius-acquired radiopharmaceutical platform at Solve, especially in targeted radiodiagnostics and radiotherapeutics for solid tumors.

Emerging players

  • ProfoundBio: Clinical-stage ADC developer focused on solid tumors with proprietary linker technology. Comparable as an early-stage ADC platform peer that was acquired by Genmab in 2024.
  • Tubulis: Emerging ADC platform company developing proprietary linkers (P5 Conjugate, Tub-tag) for solid tumors. Comparable as an early-stage ADC platform competitor with linker-focused differentiation.
  • Pyxis Oncology: Clinical-stage ADC developer (microtubule-inhibitor and topoisomerase-based payloads) with a focus on solid tumors. Comparable as a similarly staged, similarly capitalized ADC competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Solve Therapeutics social profiles

Digital presence

Solve Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solve Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Solve Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Solve Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solve Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solve Therapeutics

What does Solve Therapeutics do?

Solve Therapeutics is a clinical-stage biopharmaceutical company developing Antibody Drug Conjugates (ADCs) and Bispecific Therapeutics for solid tumor malignancies. Its lead ADC programs, SLV-154 and SLV-324, are in Phase 1 clinical trials, with a third preclinical ADC (ADC 3) and a Bispecific Therapeutic Platform in earlier-stage development. The company leverages its proprietary CloakLink™ hydrophilic linker technology to design ADCs with enhanced plasma stability, improved pharmacokinetics, and reduced off-target toxicity, and complements this with a companion Diagnostic Platform for precision patient identification.

Is Solve Therapeutics a public or private company?

Solve Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Solve Therapeutics founded?

Solve Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Solve Therapeutics based?

Solve Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Solve Therapeutics make money?

Two revenue lines are on record. ADC Therapeutic Pipeline is the primary driver. The others are diagnostic Platform.

Who are Solve Therapeutics's main competitors?

Direct peers on record are Seagen, ImmunoGen, Mersana Therapeutics and VelosBio. Broad incumbents are AstraZeneca, Daiichi Sankyo and Telix Pharmaceuticals. Emerging players are ProfoundBio, Tubulis and Pyxis Oncology.

Does Solve Therapeutics have an API?

No public API is recorded for Solve Therapeutics.

What industry is Solve Therapeutics in?

Solve Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DSolve Therapeutics, Inc., a Delaware-incorporated biotechnology company headquartered in Belmont, California, filed a Form D notice with the SEC for an exempt offering of equity securities under Rule 506(c), with first sales occurring on November 14, 2025. The filing discloses a total offering amount of approximately $120.5 million, of which $48.2 million has already been sold to 16 investors, leaving $72.3 million remaining to be sold. The CEO David Johnson signed the filing on November 24, 2025, with no minimum investment requirement, sales commissions, or finder's fees reported.BioXconomy$120m solution: Solve Therapeutics tackle ADC issueSolve Therapeutics has secured $120 million in financing to accelerate the clinical development of its CloakLink-enabled antibody drug conjugates, SLV-154 and SLV-324. The round was led by Yosemite, with participation from Abingworth, Merck, and Alexandria Venture Investments, bringing the company's total funding to $321 million.YahooSolve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid TumorsSolve Therapeutics, a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, raised $120 million in an oversubscribed Series B financing round led by Yosemite with participation from investors including Abingworth, Ally Bridge Group, Merck & Co., and SymBiosis. The funding will accelerate development of lead programs SLV-154 and SLV-324 (both in Phase 1 clinical trials) using the company's proprietary CloakLink™ linker platform, bringing total capital raised to $321 million. The investment follows a $75 million financing completed in December 2024 and represents a significant endorsement of the company's ADC technology designed to overcome traditional ADC limitations in treating solid tumors.The Pharma LetterSolve Therapeutics raises $120 million to advance ADC pipelineSolve Therapeutics raised $120 million in new financing to advance its antibody–drug conjugate (ADC) pipeline and expand its linker technology. The funding follows a previous $75 million raise in December 2024.FinSMEsSolve Therapeutics Raises $120 M in Upsized FundingSolve Therapeutics, a San Diego-based clinical-stage biotechnology company developing antibody-drug conjugates for solid tumor malignancies, raised $120 million in an upsized financing round led by Yosemite with participation from multiple investors including Merck & Co., Abingworth, and B Capital. The funding follows a $75 million financing in December 2024, bringing the company's total capital raised to $321 million. The company intends to use the proceeds to accelerate development of its clinical pipeline and proprietary CloakLink™ linker platform, supporting Phase 1b study completion and expansion toward later-stage clinical development.Pulse 2.0Solve Therapeutics: $120 Million To Advance Next-Generation ADC Pipeline For Solid TumorsSolve Therapeutics has secured $120 million in Series B financing led by Yosemite, with participation from investors including Merck & Co., to advance its clinical-stage antibody drug conjugates for solid tumors. The San Diego-based company is developing its proprietary CloakLink linker system, with two lead programs—SLV-154 and SLV-324—currently in Phase 1 trials. The new funding follows a $75 million raise in late 2024, bringing total capital raised to $321 million, and will support completion of Phase 1b studies and broader operational expansion.Venture Capital Access OnlineSolve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid TumorsSolve Therapeutics, a clinical-stage biotechnology company based in San Diego, announced the successful close of a $120 million oversubscribed and upsized financing round led by Yosemite, with participation from investors including Abingworth, Ally Bridge Group, Merck & Co., and others. The funding will support completion of Phase 1b studies for the company's lead ADC programs SLV-154 and SLV-324, both leveraging Solve's proprietary CloakLink™ linker technology for solid tumor treatment. This latest financing follows a $75 million round in December 2024, bringing Solve's total capital raised to $321 million since inception.VC News DailySolve Therapeutics Secures $120 MillionSolve Therapeutics, a clinical-stage biotechnology company developing antibody-drug conjugates for solid tumor malignancies, has raised $120 million in an oversubscribed and upsized financing round. The round was led by Yosemite with participation from multiple investors including Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., and SymBiosis, bringing the company's total capital raised to $321 million. The funding will accelerate the development of its clinical pipeline and proprietary CloakLink linker platform.